Chronic Obstructive Pulmonary Disease (COPD) Pipeline Analysis | Insights into the Current Therapies, Emerging Drugs, Latest Regulatory Approvals, Clinical Trials, Treatment Outlook and Key Companies
“Chronic Obstructive Pulmonary Disease (COPD) Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.
The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Chronic Obstructive Pulmonary Disease (COPD) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Chronic Obstructive Pulmonary Disease Treatment.
-
Chronic Obstructive Pulmonary Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
DelveInsight’s Report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Outlook
Globally, several major players are involved in developing therapies for chronic obstructive pulmonary disease (COPD). As per DelveInsight, Chronic Obstructive Pulmonary Disease (COPD) therapeutics market size is expected to grow in the coming years owing to the advances in the characterization of the disease, treatment options, imaging modalities, and a better understanding of the comorbidities, launch of the emerging therapies, among others.
Major Players in Chronic Obstructive Pulmonary Disease
There are approx. 70+ key companies which are developing therapies for Chronic Obstructive Pulmonary Disease. Currently, AstraZeneca has its Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage of clinical development.
Chronic Obstructive Pulmonary Disease (COPD) Emerging Drugs Analyzed in the report include:
• Benralizumab: AstraZeneca
• MV130: Inmunotek S.L.
• SB-240563: GlaxoSmithKline
• SAR440340: Sanofi/Regeneron
• CHF 6001: Chiesi Farmaceutici S.p.A.
• YPL 001: Yungjin Pharm. Co., Ltd.
And many others
Some of the key companies in the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market include:
GlaxoSmithKline, Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Astrazeneca, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring; Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, and others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease Current Treatment Patterns
4. Chronic Obstructive Pulmonary Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase-III)
7. Chronic Obstructive Pulmonary Disease Mid-Stage Products (Phase-II)
8. Chronic Obstructive Pulmonary Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Obstructive Pulmonary Disease Discontinued Products
13. Chronic Obstructive Pulmonary Disease Product Profiles
14. Key Companies in the Chronic Obstructive Pulmonary Disease Market
15. Key Products in the Chronic Obstructive Pulmonary Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Chronic Obstructive Pulmonary Disease Unmet Needs
18. Chronic Obstructive Pulmonary Disease Future Perspectives
19. Chronic Obstructive Pulmonary Disease Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Granulomatosis With Polyangiitis Market
“Granulomatosis With Polyangiitis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
 Pipeline Analysis | Insights into the Current Therapies, Emerging Drugs, Latest Regulatory Approvals, Clinical Trials, Treatment Outlook and Key Companies){kind=link}